Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Jørgensen, Charlotte L T ^a   Ejlertsen, Bent ^b   Bjerre, Karsten D ^b   Balslev, Eva ^a   Nielsen, Dorte L ^a   Nielsen, Kirsten V ^c  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b Rigshospitalet   (Denmark)

^c Centre for Innovation and Research   (Denmark)

Author keywords

Docetaxel; FISH; Gemcitabine; Gene aberrations; Metastatic breast cancer; Ribonucleotide reductase; RRM1; RRM2B

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE SUBUNIT M1 PROTEIN; RIBONUCLEOTIDE REDUCTASE SUBUNIT M2B PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADVANCED CANCER; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CENTROMERE; CHROMOSOME 11; CHROMOSOME 8; CHROMOSOME 8Q; CHROMOSOME ABERRATION; CONTROLLED STUDY; COPY NUMBER VARIATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DELETION; HUMAN; HUMAN TISSUE; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MASTECTOMY; MULTICENTER STUDY; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PHASE 3 CLINICAL TRIAL; PILOT STUDY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; RRM1 GENE; RRM2B GENE; TUMOR GENE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL CYCLE PROTEINS; DEOXYCYTIDINE; DISEASE PROGRESSION; DNA COPY NUMBER VARIATIONS; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; NEOPLASM STAGING; RIBONUCLEOTIDE REDUCTASES; TAXOIDS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS;

EID: 84887274342     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-541     Document Type: Article

References (52)

1. Nordlund P, Reichard P. Ribonucleotide reductases. Annu Rev Biochem 2006, 75:681-706. 10.1146/annurev.biochem.75.103004.142443, 16756507.
2. Jordan A, Reichard P. Ribonucleotide reductases. Annu Rev Biochem 1998, 67:71-98. 10.1146/annurev.biochem.67.1.71, 9759483.
3. Heinemann V, Xu Y-Z, Chubb S, Sen A, Hertel LW, Grindey GB, Plunkett W. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol Pharmacol 1990, 38:567-572.
4. Heinemann V, Hertel LW, Grindley GB, Plunkett W. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-beta-d-arabinofuranosylcytosine. Cancer Res 1988, 48:4024-4031.
5. Shao J, Zhou B, Chu B, Yen Y. Ribonucleotide reductase inhibitors and future drug design. Curr Cancer Drug Targets 2006, 6:409-431. 10.2174/156800906777723949, 16918309.
6. Jordheim LP, Séve P, Trédan O, Dumontet C. The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. Lancet Oncol 2011, 12:694-702.
7. Tooker P, Yen WC, Ng SC, Negro-Vilar A, Hermann TW. Bexarotene (LGD1069, Targretin), a selective retinoid X receptor agonist, prevents and reverses gemcitabine resistance in NSCLC cells by modulating gene amplification. Cancer Res 2007, 67:4425-4433. 10.1158/0008-5472.CAN-06-4495, 17483357.
8. Jordheim LP, Guittet O, Lepoivre M, Galmarini CM, Dumontet C. Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells. Mol Cancer Ther 2005, 4:1268-1276. 10.1158/1535-7163.MCT-05-0121, 16093443.
9. Gong W, Zhang X, Wu J, Chen L, Li L, Sun J, Lv Y, Wei X, Du Y, Jin H, Dong J. RRM1 expression and clinical outcome of gemcitabine-containing chemotherapy for advanced non-small-cell lung cancer: a meta-analysis. Lung Cancer 2012, 75:374-380. 10.1016/j.lungcan.2011.08.003, 21889227.
10. Bepler G, Sommers KE, Cantor A, Li X, Sharma A, Williams C, Chiappori A, Haura E, Antonia S, Tanvetyanon T, Simon G, Obasaju C, Robinson LA. Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer. J Thorac Oncol 2008, 3:1112-1118. 10.1097/JTO.0b013e3181874936, 2639211, 18827606.
11. Reynolds C, Obasaju C, Schell MJ, Li X, Zheng Z, Boulware D, Caton JR, Demarco LC, O'Rourke MA, Shaw Wright G, Boehm KA, Asmar L, Bromund J, Peng G, Monberg MJ, Bepler G. Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol 2009, 27:5808-5815. 10.1200/JCO.2009.21.9766, 2793001, 19884554.
12. Su C, Zhou S, Zhang L, Ren S, Xu J, Zhang J, Lv M, Zhang J, Zhou C. ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer. Med Oncol 2011, 28:1411-1417. 10.1007/s12032-010-9553-9, 20467918.
13. Vilmar AC, Santoni-Ruqiu E, Sorensen JB. Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomly assigned in a chemotherapy phase III trial. Ann Oncol 2013, 24:309-314. 10.1093/annonc/mds335, 23038758.
14. Davidson JD, Ma L, Flagella M, Geeganage S, Gelbert LM, Slapak CA. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res 2004, 64:3761-3766. 10.1158/0008-5472.CAN-03-3363, 15172981.
15. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene 2004, 23:1539-1548. 10.1038/sj.onc.1207272, 14661056.
16. Boukovinas I, Papadaki C, Mendez P, Taron M, Mavroudis D, Koutsopoulos A, Sanchez-Ronco M, Sanchez JJ, Trypaki M, Staphopoulos E, Georgoulias V, Rosell R, Souglakos J. Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients. PLoS One 2008, 3:e3695. 10.1371/journal.pone.0003695, 2579656, 19002265.
17. Souglakos J, Boukovinas I, Taron M, Mendez P, Mavroudis D, Tripaki M, Hatzidaki D, Koutsopoulos A, Stathopoulos E, Georgoulias V, Rosell R. Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine. Br J Cancer 2008, 98:1710-1715. 10.1038/sj.bjc.6604344, 2391126, 18414411.
18. Sato J, Kimura T, Saito T, Anazawa T, Kenjo A, Sato Y, Tsuchiya T, Gotoh M. Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma. J Hepatobiliary Pancreat Sci 2011, 18:700-711. 10.1007/s00534-011-0376-7, 21451941.
19. Nielsen DL, Bjerre KD, Jakobsen EH, Cold S, Stenbygaard L, Sorensen PG, Kamby C, Moller S, Jorgensen CL, Andersson M. Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: a randomized, phase III study by the Danish breast cancer cooperative group. J Clin Oncol 2011, 29:4748-4754. 10.1200/JCO.2010.33.9507, 22084374.
20. Smid M, Hoes M, Sieuwerts AM, Sleijfer S, Zhang Y, Wang Y, Foekens JA, Martens JW. Patterns and incidence of chromosomal instability and their prognostic relevance in breast cancer subtypes. Breast Cancer Res Treat 2011, 128:23-30. 10.1007/s10549-010-1026-5, 20632083.
21. Weigman VJ, Chao HH, Shabalin AA, He X, Parker JS, Nordgard SH, Grushko T, Huo D, Nwachukwu C, Nobel A, Kristensen VN, Borresen-Dale AL, Olopade OI, Perou CM. Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival. Breast Cancer Res Treat 2012, 133:865-880. 10.1007/s10549-011-1846-y, 3387500, 22048815.
22. Henriksen KL, Rasmussen BB, Lykkesfeldt AE, Moller S, Ejlertsen B, Mouridsen HT. Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays. J Clin Pathol 2007, 60:397-404. 2001128, 16775123.
23. Nielsen KV, Ejlertsen B, Muller S, Moller S, Rasmussen BB, Balslev E, Laenkholm AV, Christiansen P, Mouridsen HT. Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer. Breast Cancer Res Treat 2011, 127:345-355. 10.1007/s10549-010-0984-y, 20556506.
24. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, Statistics Subcommittee of the NCIEWGoCD REporting recommendations for tumour MARKer prognostic studies (REMARK). Eur J Cancer 2005, 41:1690-1696. 10.1016/j.ejca.2005.03.032, 16043346, Statistics Subcommittee of the NCIEWGoCD.
25. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009, 101:1446-1452. 10.1093/jnci/djp335, 2782246, 19815849.
26. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009, 27:1160-1167. 10.1200/JCO.2008.18.1370, 2667820, 19204204.
27. Saito S, Morita K, Hirano T. High frequency of common DNA copy number abnormalities detected by bacterial artificial chromosome array comparative genomic hybridization in 24 breast cancer cell lines. Hum Cell 2009, 22:1-10. 10.1111/j.1749-0774.2008.00061.x, 19222606.
28. Fridlyand J, Snijders AM, Ylstra B, Li H, Olshen A, Segraves R, Dairkee S, Tokuyasu T, Ljung BM, Jain AN, McLennan J, Ziegler J, Chin K, Devries S, Feiler H, Gray JW, Waldman F, Pinkel D, Albertson DG. Breast tumor copy number aberration phenotypes and genomic instability. BMC Cancer 2006, 6:96. 10.1186/1471-2407-6-96, 1459181, 16620391.
29. Albertson DG, Collins C, McCormick F, Gray JW. Chromosome aberrations in solid tumors. Nat Genet 2003, 34:369-376. 10.1038/ng1215, 12923544.
30. Winqvist R, Hampton GM, Mannermaa A, Blanco G, Alavaikko M, Kiviniemi H, Taskinen PJ, Evans GA, Wright FA, Newsham I, Cavenee WK. Loss of heterozygosity for chromosome 11 in primary human breats tumors is assocaited with poor survival after metastasis. Cancer Res 1995, 55:2660-2664.
31. Bepler G, Gercia-Blanco MA. Three tumor-suppressor regions on chromosome 11p identified by high-resolution deletion mapping in human non-small-cell lung cancer. Proc Natl Acad Sci U S A 1994, 91:5513-5517. 10.1073/pnas.91.12.5513, 44026, 8202519.
32. Akita H, Zheng Z, Takeda Y, Kim C, Kittaka N, Kobayashi S, Marubashi S, Takemasa I, Nagano H, Dono K, Nakamori S, Monden M, Mori M, Doki Y, Bepler G. Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma. Oncogene 2009, 28:2903-2909. 10.1038/onc.2009.158, 19543324.
33. Bepler G, Sharma S, Cantor A, Gautam A, Haura E, Simon G, Sharma A, Sommers E, Robinson L. RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer. J Clin Oncol 2004, 22:1878-1885. 10.1200/JCO.2004.12.002, 15143080.
34. Harshman LC, Bepler G, Zheng Z, Higgins JP, Allen GI, Srinivas S. Ribonucleotide reductase subunit M1 expression in resectable, muscle-invasive urothelial cancer correlates with survival in younger patients. BJU Int 2010, 106:1805-1811. 10.1111/j.1464-410X.2010.09327.x, 3768117, 20438561.
35. Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007, 356:800-808. 10.1056/NEJMoa065411, 17314339.
36. Rennstam K, Ahlstedt-Soini M, Baldetrop B, Bendahl P-O, Borg T, Karhu R, Tanner M, Tirkkonen M, Isola J. Patterns of chromosomal imbalances defines subgroups of breast cancer with distinct clinical fetures and prognosis: a study of 305 tumors by compartive genomic hybridization. Cancer Res 2003, 63:8861-8868.
37. Blegen H, Will JS, Ghadimi M, Nash H-P, Zetterberg A, Auer G, Ried T. DNA amplifications and aneuploidy, high proliferative activity and impaired cell cycle control characterize breast carcinomas with poor prognosis. Anal Cell Pathol 2003, 25:103-114.
38. Hsu N-Y, Wu J-Y, Liu X, Yen Y, Chen C-Y, Chou M-C, Lin C-H, Lee H, Cheng Y-W. Expression status of ribonucleotide reductase small subunits hRRM2/p53R2 as prognostic biomarkers in stage I and II non-small cell lung cancer. Anticancer Res 2011, 31:3475.
39. Hsu NY, Wu JY, Liu X, Yen Y, Chen C-Y, Chou M-C, Lee H, Cheng Y-W. p53R2 expression as a prognostic biomarker in early stage non-small cell lung cancer. Oncology Lett 2010, 1:609.
40. Liu X, Lai L, Wang X, Xue L, Leora S, Wu J, Hu S, Zhang K, Kuo ML, Zhou L, Zhang H, Wang Y, Wang Y, Zhou B, Nelson RA, Zheng S, Zhang S, Chu P, Yen Y. Ribonucleotide reductase small subunit M2B prognoses better survival in colorectal cancer. Cancer Res 2011, 71:3202-3213. 10.1158/0008-5472.CAN-11-0054, 3085570, 21415168.
41. Okumura H, Natsugoe S, Yokomakura N, Kita Y, Matsumoto M, Uchikado Y, Setoyama T, Owaki T, Ishigami S, Aikou T. Expression of p53R2 is related to prognosis in patients with esophageal squamous cell carcinoma. Clin Cancer Res 2006, 12:3740-3745. 10.1158/1078-0432.CCR-05-2416, 16778101.
42. Uramoto HSK, Oyama T, Hanagiri T, Yasumoto K. p53R2, p53 inducible ribonucleotide reductase gene, correlated with tumor progression of non-small cell lung cancer. Anticancer Res 2006, 26:983-988.
43. Bepler G, Williams C, Schell MJ, Chen W, Zheng Z, Simon G, Gadgeel S, Zhao X, Scheiber F, Brahmer J, Chiappori A, Tanvetyanon T, Pinder-Schenck M, Gray J, Haure E, Antonia S, Fischer JR. Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2013, 31:2404-2412. 10.1200/JCO.2012.46.9783, 23690416.
44. Metro G, Zheng Z, Fabi A, Schell M, Antoniani B, Mottolese M, Monteiro AN, Vici P, Lara Rivera S, Boulware D, Cognetti F, Bepler G. In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy. Cancer Invest 2010, 28:172-180. 10.3109/07357900903095722, 3565222, 19968494.
45. Chabalier C, Lamare C, Racca C, Privat M, Valette A, Larminat E. BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. Cell Cycle 2006, 5:1001-1007. 10.4161/cc.5.9.2726, 16639080.
46. Albertson DG. Gene amplification in cancer. Trends Genet 2006, 22:447-455. 10.1016/j.tig.2006.06.007, 16787682.
47. Melchor L, Alvarez S, Honrado E, Palacios J, Barroso A, Diez O, Osorio A, Benitez J. The accumulation of specific amplifications characterizes two different genomic pathways of evolution of familial breast tumors. Clin Cancer Res 2005, 11:8577-8584. 10.1158/1078-0432.CCR-05-1278, 16361540.
48. Kim D, Jung W, Koo JS. The expression of ERCC1, RRM1, and BRCA1 in breast cancer according to the immunohistochemical phenotypes. J Korean Med Sci 2011, 26:352-359. 3051081, 21394302.
49. Chang HJ, Han SW, Oh DY, Im SA, Jeon YK, Park IA, Han W, Noh DY, Bang YJ, Kim TY. Discordant human epidermal growth factor receptor 2 and hormone receptor status in primary and metastatic breast cancer and response to trastuzumab. Jpn J Clin Oncol 2011, 41:593-599. 10.1093/jjco/hyr020, 21406492.
50. Xiao C, Gong Y, Han EY, Gonzalez-Angulo AM, Sneige N. Stability of HER2-positive status in breast carcinoma: a comparison between primary and paired metastatic tumors with regard to the possible impact of intervening trastuzumab treatment. Ann Oncol 2011, 22:1547-1553. 10.1093/annonc/mdq623, 21239403.
51. Bepler G, Zheng Z, Gautam A, Sharma S, Cantor A, Sharma A, Cress WD, Kim YC, Rosell R, McBride C, Robinson L, Sommers E, Haura E. Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance. Lung Cancer 2005, 47:183-192. 10.1016/j.lungcan.2004.07.043, 15639717.
52. Dong S, Guo A-L, Chen Z-H, Wang Z, Zhang X-C, Huang Y, Xie Z, Yan H-H, Cheng H, Wu Y-L. RRM1 single nucleotide polymorphism -37C- > A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy. J Hematol Oncol 2010, 3:10. 10.1186/1756-8722-3-10, 2855513, 20226083.